RAPIDTEST

Founded in 2004, BMT Diagnostics is an Israeli company with a business focus on providing rapid diagnostic solutions to the point-of-care (POC) and for self-testing.

BMT Diagnostics was the first company to introduce rapid tests for Strep A diagnosis to Israeli pharmacies, allowing patients to purchase these tests over-the-counter (OTC) prior to visiting their primary care physician. This strategy aimed at improving the process of patient`s screening at the physician`s office, thereby reducing antibiotics abuse by preventing their administration to patients tested negative for Strep A. An additional goal for this strategy was to shift Strep A screening from centralized labs to point-of-care, improving HMO service at times the centralized lab was inoperative (e.g., weekends) or overloaded. 

In recent years, BMT has captured an additional market segment by selling its tests directly to leading HMOs who distribute them internally in their clinics. Of the estimated two million Strep A tests performed annually in Israel, around 500,000 are RDT, thereby validating our business model that is based on patients assuming responsibility for their own health first, followed by ENT and family physician’s adoption and acceptance of Strep A RDT as a first-line diagnostic standard. 

BMT develops, manufactures, distributes and sells a range of rapid diagnostic tests (RDT) in the following disease and healthcare areas: 

Infectious disease

Fertility

Early markers of disease

Urinalysis and urinary tract infection (UTI)

Drugs of abuse

 

R&D   

Having identified the need for more user-friendly and accurate rapid diagnostic tests, BMT has developed a patent-pending, novel and innovative diagnostic device platform that greatly simplifies rapid diagnostic testing by minimizing the number of kit components and test performance steps. 

Applying this new platform to Strep A diagnosis reduced performance complexity to a single step, making it simpler and more intelligible. This new platform is likely to increase Strep A test usability and adoption by physicians and other healthcare providers. The Strep A diagnostic device is CE-marked and currently distributed in Israel and Europe under our Lab-On-TimeTM.

BMT is constantly in the process of expanding its product line, both by improving its existing products and adding novel ones to its portfolio. We are seeking both, distributors in major territories for our current products and OEM collaborations with diagnostics product manufacturers to co-develop additional applications for our core technologies.